C
Center for Retina and Macular Disease | Winter Haven, FL
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
APL-2
Aflibercept
Pegcetacoplan
Tarcocimab
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 4 total trials
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.
Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...
Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...
Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)
Trial sponsors
A
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems